TNI-97

• Description:

  TNI-97 is a selective and orally active HDAC6 inhibitor, with an IC50 of 0.2 nM. TNI-97 potently inhibited TNBC cell MDA-MB-453 growth and clonogenicity. TNI-97 induces PANoptosis including apoptosis, necroptosis and pyroptosis in MDA-MB-453 cells. TNI-97 shows antitumor activity in the mice carrying the MDA-MB-453 xenograft or carrying murine-derived TNBC cell allografts. TNI-97 can be used for the study of triple-negative breast cancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; HDAC; Necroptosis; Pyroptosis

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  CN1N=NC2=C1C=CC(C3=NN(CC4=CC=C(C=C4)C(NO)=O)C(C(F)(F)F)=C3)=C2

• Molecular Formula:

  C19H15F3N6O2

• Molecular Weight:

  416.36

• References & Citations:

  [1]Wang S, et al. Discovery of TNI-97 as a Highly Selective, Orally Bioavailable HDAC6 Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2025 Jul 24;68 (14) :14333-14356.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9

• CAS Number:

  [2790425-52-2]